Patents by Inventor Jiun-Ming Wu
Jiun-Ming Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240151972Abstract: An augmented reality (AR) display is provided. The display comprises a light field generator and a birdbath eyepiece. The light field generator generates a light field as an output. The birdbath eyepiece connects to the light field generator for receiving and projecting the light field to human eye. The birdbath eyepiece comprises a beam splitter and a combiner. The combiner has a curved surface. Each beam of the light field is split into two beams by the beam splitter with one of the split beams reflected by the combiner. Three states-of-use of the birdbath eyepiece are provided for the near-eye light field AR display to transmit the light field to the human eye. A low f-number (or focal ratio) and a large eyebox are obtained to effectively expand the field of view and increase the volume of space within which the human eye can receive the light field.Type: ApplicationFiled: July 27, 2023Publication date: May 9, 2024Inventors: Chao-Chien Wu, Jiun-Woei Huang, Hong-Ming Chen
-
Patent number: 11931187Abstract: A method for predicting clinical severity of a neurological disorder includes steps of: a) identifying, according to a magnetic resonance imaging (MRI) image of a brain, brain image regions each of which contains a respective portion of diffusion index values of a diffusion index, which results from image processing performed on the MRI image; b) for one of the brain image regions, calculating a characteristic parameter based on the respective portion of the diffusion index values; and c) calculating a severity score that represents the clinical severity of the neurological disorder of the brain based on the characteristic parameter of the one of the brain image regions via a prediction model associated with the neurological disorder.Type: GrantFiled: March 16, 2018Date of Patent: March 19, 2024Assignees: Chang Gung Medical Foundation Chang Gung Memorial Hospital at Keelung, Chang Gung Memorial Hospital, Linkou, Chang Gung UniversityInventors: Jiun-Jie Wang, Yi-Hsin Weng, Shu-Hang Ng, Jur-Shan Cheng, Yi-Ming Wu, Yao-Liang Chen, Wey-Yil Lin, Chin-Song Lu, Wen-Chuin Hsu, Chia-Ling Chen, Yi-Chun Chen, Sung-Han Lin, Chih-Chien Tsai
-
Patent number: 11054526Abstract: A satellite positioning module is provided, including: a receiver configured for receiving satellite signals from a plurality of satellites; and a processor connected to the receiver and configured for: performing an operation based on the satellite signals to obtain an elevation angle standard deviation; performing an operation based on the elevation angle standard deviation to obtain an elevation angle mask value; selecting a satellite signal of a satellite that has an elevation angle greater than the elevation angle mask value based on the satellite signals of the satellites to perform a positioning algorithm; and performing the positioning algorithm to obtain position information. A satellite positioning method is also provided.Type: GrantFiled: December 27, 2018Date of Patent: July 6, 2021Assignee: Industrial Technology Research InstituteInventors: Jiun-Ming Wu, Cheng-Yun Ho
-
Publication number: 20200191976Abstract: A satellite positioning module is provided, including: a receiver configured for receiving satellite signals from a plurality of satellites; and a processor connected to the receiver and configured for: performing an operation based on the satellite signals to obtain an elevation angle standard deviation; performing an operation based on the elevation angle standard deviation to obtain an elevation angle mask value; selecting a satellite signal of a satellite that has an elevation angle greater than the elevation angle mask value based on the satellite signals of the satellites to perform a positioning algorithm; and performing the positioning algorithm to obtain position information. A satellite positioning method is also provided.Type: ApplicationFiled: December 27, 2018Publication date: June 18, 2020Inventors: Jiun-Ming Wu, Cheng-Yun Ho
-
Patent number: 10058606Abstract: A fusion protein for use as a hepatitis B therapeutic vaccine is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen comprising a hepatitis B virus X protein deletion mutant that lacks amino acids (aa) at least from as 21 to as 50. The protein transduction domain is a fusion polypeptide comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide. The APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen is located at the C-terminus of the protein transduction domain.Type: GrantFiled: September 11, 2017Date of Patent: August 28, 2018Assignee: TheVax Genetics Vaccine Co., Ltd.Inventors: Chia-Mao Wu, Jiun-Ming Wu, Yi-Chia Lin, Kung-Lung Lee, Chia-Hao Kang, Fu-Hsien Chiang, Cheng-Yung Chang, Wei-Lun Chang, Hsiang-Kai Lin, Chia-Kuan Peng, Wei-Hsiang Lin, Yi-Tsui Chiu
-
Publication number: 20180078636Abstract: A fusion protein for use as a hepatitis B therapeutic vaccine is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen comprising a hepatitis B virus X protein deletion mutant that lacks amino acids (aa) at least from as 21 to as 50. The protein transduction domain is a fusion polypeptide comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide. The APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen is located at the C-terminus of the protein transduction domain.Type: ApplicationFiled: September 11, 2017Publication date: March 22, 2018Inventors: Chia-Mao WU, Jiun-Ming Wu, Yi-Chia Lin, Kung-Lung Lee, Chia-Hao Kang, Fu-Hsien Chiang, Cheng-Yung Chang, Wei-Lun Chang, Hsiang-Kai Lin, Chia-Kuan Peng, Wei-Hsiang Lin, Yi-Tsui Chiu
-
Patent number: 9775898Abstract: Vaccine compositions for use in inducing enhanced antigen-specific T cell-mediated immune responses in a subject in need thereof are disclosed. The composition comprises (a) a therapeutically effective amount of an immunogenic protein comprising at least an antigen of a pathogen; (b) a saponin-base adjuvant selected from the group consisting of GPI-0100, Quil A, QS-21; and (c) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG1826.Type: GrantFiled: February 24, 2016Date of Patent: October 3, 2017Assignee: TheVax Genetics Vaccine Co., Ltd.Inventors: Chia-Mao Wu, Jiun-Ming Wu, Yi-Tsui Chiu, Yin-Ching Lin, Hsien-Kai Chuang, Fu-Tan Hsieh, Kuan-Ming Chen
-
Patent number: 9676826Abstract: A vaccine composition comprising a fusion protein for inducing enhanced pathogen antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein; (b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 2, 3, or 6, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and (c) an antigen of a pathogen, located at the C-terminus of the translocation peptide; (d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 13; and (e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein.Type: GrantFiled: April 13, 2016Date of Patent: June 13, 2017Assignee: TheVax Genetics Vaccine Co., Ltd.Inventors: Wei-I Chou, Chia-Mao Wu, Jiun-Ming Wu, Hsiu-Kang Chang
-
Publication number: 20160250324Abstract: Vaccine compositions for use in inducing enhanced antigen-specific T cell-mediated immune responses in a subject in need thereof are disclosed. The composition comprises (a) a therapeutically effective amount of an immunogenic protein comprising at least an antigen of a pathogen; (b) a saponin-base adjuvant selected from the group consisting of GPI-0100, Quil A, QS-21; and (c) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG1826.Type: ApplicationFiled: February 24, 2016Publication date: September 1, 2016Inventors: Chia-Mao WU, Jiun-Ming Wu, Yi-Tsui Chiu, Yin-Ching Lin, Hsien-Kai Chuang, Fu-Tan Hsieh, Kuan-Ming Chen
-
Publication number: 20160229896Abstract: A vaccine composition comprising a fusion protein for inducing enhanced pathogen antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein; (b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 2, 3, or 6, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and (c) an antigen of a pathogen, located at the C-terminus of the translocation peptide; (d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 13; and (e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein.Type: ApplicationFiled: April 13, 2016Publication date: August 11, 2016Inventors: WEI-I CHOU, Chia-Mao Wu, Jiun-Ming Wu, Hsiu-Kang Chang
-
Patent number: 9339536Abstract: A vaccine composition comprising a fusion protein for inducing enhanced pathogen antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein; (b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 2, 3, or 6, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and (c) an antigen of a pathogen, located at the C-terminus of the translocation peptide; (d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 13; and (e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein.Type: GrantFiled: December 3, 2013Date of Patent: May 17, 2016Assignee: TheVax Genetics Vaccine Co., Ltd.Inventors: Wei-I Chou, Chia-Mao Wu, Jiun-Ming Wu, Hsiu-Kang Chang
-
Publication number: 20140154280Abstract: A vaccine composition comprising a fusion protein for inducing enhanced pathogen antigen-specific T cell responses is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain, located at the N-terminus of the fusion protein; (b) a translocation peptide of 34-112 amino acid residues in length, comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 2, 3, or 6, located at the C-terminus of the APC-binding domain or the CD91 receptor-binding domain; and (c) an antigen of a pathogen, located at the C-terminus of the translocation peptide; (d) a nuclear export signal, comprising the amino acid sequence of SEQ ID NO: 13; and (e) an endoplasmic reticulum retention sequence, located at the C-terminus of the fusion protein.Type: ApplicationFiled: December 3, 2013Publication date: June 5, 2014Applicant: TheVax Genetics Vaccine Co., Ltd.Inventors: Wei-I CHOU, Chia-Mao Wu, Jiun-Ming Wu, Hsiu-Kang Chang
-
Patent number: 8386381Abstract: According to an embodiment of the present invention, an automated computer implemented method for detecting one or more data compromises comprises the steps of detecting an activity indicative of a data compromise based at least in part on a compromise detection report involving at least one of merchant compromise report, region compromise report and acquirer compromise report, wherein the compromise detection report is generated by an automated detection algorithm; classifying the activity based on a combination of risk level, size of data compromise and fraud severity; and identifying a specific mitigation response to the activity through an interface. Another embodiment of the present invention determines whether one or more accounts associated with the activity have been probed or tested by a fraudster to determine if the one or more accounts are valid.Type: GrantFiled: December 16, 2009Date of Patent: February 26, 2013Assignee: JPMorgan Chase Bank, N.A.Inventors: Thomas C. Barton, Sandhya Kumar, Charu Mehta, Harold Paulson, Jr., Geetha Vaidyanathan, Jiun-Ming Wu